Can Downer EDI (ASX: DOW) turn the Chevron contract into long-term earnings momentum?
Downer EDI Limited’s A$750M Chevron contract and FY25 earnings growth reinforce its turnaround story. Find out why institutional sentiment is improving. Read More
Mont Royal Resources and Commerce Resources complete merger to advance Ashram rare earth project in Québec
Mont Royal Resources and Commerce Resources complete rare earths merger. Learn how the Ashram Project positions MRZ as a major player in North American critical ... Read More
Brisbane’s digital bank play: How Bank of Queensland’s FY25 results reflect a sharp pivot to higher-margin lending
Find out how Bank of Queensland Limited (ASX: BOQ) boosted cash profits by 12% in FY25 through commercial lending growth, digital execution, and disciplined cost ... Read More
Locksley Resources (ASX: LKY) hits 68% antimony concentrate—could this mark the rebirth of U.S. supply?
Locksley Resources expands its Mojave Project with a 400% strike gain and 68% antimony concentrate—discover how this could redefine U.S. critical minerals supply. Read More
Electro Optic Systems (ASX: EOS) rockets 600 % as LAND 400-3 contract ignites defence sector momentum
Find out how Electro Optic Systems’ A$108 million LAND 400-3 win drives its 600 % ASX rally and reshapes Australia’s defence supply chain. Read More
DXB rockets on Japan orphan drug win — can Dimerix finally deliver an FSGS breakthrough?
Dimerix (ASX: DXB) secures orphan drug designation in Japan for DMX-200, strengthening its global Phase 3 kidney trial program. Find out what’s next. Read More
Carawine Resources set for ASX delisting after QGold wins court battle over compulsory buyout
QGold secures full control of Carawine Resources after Federal Court approval, ending a year-long dispute and paving the way for ASX delisting at AUD 0.11 ... Read More
Can Alterity Therapeutics’ penny stock (ASX: ATH) ride ATH434’s $2.4bn market potential to long-term gains?
Alterity Therapeutics eyes $2.4B peak sales for ATH434 in Multiple System Atrophy. Can this small-cap biotech turn clinical promise into commercial reality? Read More
Is Emyria (ASX: EMD) stock ready to re-rate after Medibank funds its TRD program?
Emyria (ASX: EMD) secures Medibank backing for its TRD program, marking a milestone for insurer-funded mental health care. Can the stock sustain momentum? Read More
Seven sectors up, four sectors down — the ASX winners and losers you need to know
Find out how ASX sectors moved on September 19, 2025 — healthcare and technology led the gains while telecoms and staples lagged. Read More